Document is current
Any future updates will be listed below
-
Authors
Ju, Wenjun https://orcid.org/0000-0002-9136-8454
Nair, Viji
Vart, Priya
Smeijer, J. David
Hudkins, Kelly L.
Moedt, Erik https://orcid.org/0009-0003-3983-5136
Larkina, Maria
Perco, Paul https://orcid.org/0000-0003-2087-5691
Burdet, Frédéric https://orcid.org/0000-0002-2923-827X
Shedden, Kerby
Hwang, Michael https://orcid.org/0009-0002-5546-6812
Lee, Edmond https://orcid.org/0009-0009-2443-6638
O’Connor, Christopher
Hartman, John
Subramanian, Lalita
Bitzer, Markus https://orcid.org/0000-0002-3711-2984
Ibberson, Mark https://orcid.org/0000-0003-3152-5670
Duffin, Kevin L.
Gomez, Maria F. https://orcid.org/0000-0001-6210-3142
Alpers, Charles E. https://orcid.org/0000-0002-1859-1772
Kretzler, Matthias
Heerspink, Hiddo J. L. https://orcid.org/0000-0002-3126-3730
- License Information
-
More Information
Article History
Received: 28 February 2025
Accepted: 12 January 2026
First Online: 7 February 2026
Competing interests
: M.K. reports grants and contracts through the University of Michigan unrelated of this work from Chan Zuckerberg Initiative, AstraZeneca, NovoNordisk, Eli Lilly, Boehringer-Ingelheim, European Union Innovative Medicine Initiative, Certa Therapeutics, RenalytixAI, Regeneron, Novo Nordisk, Sanofi, Dimerix, Travere and Vera Therapeutics. Also outside of this work, M.K. has received consulting fees through the University of Michigan from NovoNordisk, Alexion, Novartis, Roche Diagnostics and Vera Therapeutics. W.J., V.N., and M.K. hold a patent PCT/EP2014/073413 “Biomarkers and methods for progression prediction for chronic kidney disease” licensed. P.P. is an employee at Delta4 GmbH. Unrelated to this work, W.J. received consultancy fees from Travere Therapeutics. M.F.G. has received financial and non-financial (in kind) support from Boehringer Ingelheim Pharma GmbH, JDRF International, Eli Lilly, AbbVie, Sanofi-Aventis, Astellas, Novo Nordisk A/S, Bayer AG, within EU grant H2020-JTI-lMl2-2015-05 (Grant agreement number 115974 - BEAt-DKD): She has also received financial and in kind support from Novo Nordisk, Pfizer, Follicum, Coegin Pharma, Abcentra, Probi, Johnson & Johnson, within a project funded by the Swedish Foundation for Strategic Research on precision medicine in diabetes (LUDC-IRC #15-0067). MFG has received personal consultancy fees from Lilly and Tribune Therapeutics AB. The remaining authors declare no competing interests.
